Adaptive clinical trial designs in oncology

Chinese Clinical Oncology

Volumn 3, Issue 4, 2014, Pages

  Zang, Yong ^a   Lee, J Jack ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive design; Adaptive randomization; Biomarker guided design; Interim analysis; Seamless design

Indexed keywords

EID: 84941349403     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2014.06.04     Document Type: Review

References (102)

1. Pocock SJ. eds. Clinical trials: a practical approach. Chichester: Wiley, 1983.
2. Piantadosi S. eds. Clinical trials: a methodologic perspective. Hoboken: Wiley-Interscience, 2005.
3. Bio/BioMedTracker. Clinical Trial Success Rates Study, 2011. Available online: http://insidebioia.files.wordpress.com/2011/02/bio-ceo-biomedtracker-bio-study-handout-final-2-15-2011.pdf
4. Woodcock J. FDA introduction comments: clinical studies design and evaluation issues. Clinical trials 2005;2:273-5.
5. U.S. Food and Drug Administration. Critical Path Opportunities List, 2006. Available online: http://www.fda.gov/downloads/scienceresearch/specialtopics/criticalpathinitiative/criticalpathopportunitiesreports/UCM077258.pdf
6. Gallo P, Chuang S, Dragalin V, et al. Executive summary of the PhRMA working group on adaptive designs in clinical drug development. J Biopharm Stat 2006;16:275-83.
7. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006;5:27-36.
8. Chow SC, Chang M. eds. Adaptive design methods in clinical trials. City: Chapman/& Hall/CRC, 2006.
9. Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med 2012;31:2955-72.
10. Berry SM, Carlin BP, Lee JJ, et al. eds. Bayesian adaptive methods for clinical trials. Boca Raton, FL: Chapman and Hall/CRC, 2010.
11. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011;9:199-207.
12. Ying G. eds. Clinical trial design: Bayesian and frequentist adaptive methods. New Jersey: Wiley, 2012.
13. FDA Guidance for industry: Adaptive design clinical trials for drugs and biologics. U.S. Department of Health and Human Services, Food and Drug Administration (CDER/CBER). Available online: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf
14. Storer BE. Design and analysis of Phase I clinical trials. Biometrics 1989;45:925-37.
15. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 1997;89:1138-47.
16. O'Quigley J, Pepe M, Fisher LD. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 1990;46:33-48.
17. Faries D. Practical modification of the continual reassessment methods for phase I clinical trials. J Biopharm Stat 1994;4:147-64.
18. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment methods to phase I studies. Stat Med 1995;14:1149-61.
19. Yin G, and Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. J Am Stat Assoc 2009;104:954-68.
20. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 1998;17:1103-20.
21. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000;56:1177-82.
22. Yuan Y, Yin G. Robust EM continual reassessment method in oncology dose finding. J Am Stat Assoc 2011;106:818-31.
23. Liu S, Yin G, Yuan Y. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Ann Appl Stat 2013;7:1837-2457.
24. Thall PF, Cook J. Dose-finding based on efficacy-toxicity trade-off. Biometrics 2004;60:684-93.
25. Yuan Y, Yin G. Bayesian dose finding by jointly modeling toxicity and efficacy as time-to-event outcomes. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2009;58:719-36.
26. Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials 2014;11:319-27.
27. Zhang W, Sargent DJ, Mandrekar SJ. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med 2006;25:2365-83.
28. Polley MY, Cheung YK. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests. Biometrics 2008;64:232-41.
29. Thall PF, Millikan R, Muller P, et al. Dose-finding with two agents in phase I oncology trials. Biometrics 2003;59:487-96.
30. Yin G, Yuan Y. Bayesian dose-finding in oncology for drug combination by coupla regression. Journal of the Royal Statistical Society, Series C 2009;58:211-24.
31. Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose findings. Stat Med 2008;27:5664-78.
32. Yin G, Yuan Y. A latent contingency table approach to dose-finding for combinations of two agents. Biometrics 2009;65:866-75.
33. Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 2007;26:2317-30.
34. Braun TM. The current design of oncology phase I clinical trials: progressing from algorithms to statistical models. Chin Clin Oncol 2014;3:2.
35. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
36. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
37. Pocock SJ. Group sequential method in the design and analysis of clinical trials. Biometrika 1977;64:191-9.
38. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
39. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987;43:193-9.
40. DeMets DL, Lan KK. Interim analyses: the alpha spending function approach. Stat Med 1994;13:1341-52.
41. Jennison C, Turnbull BW. eds. Group sequential tests with application to clinical trials. Boca Raton: Chapman and Hall/CRC, 2000.
42. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995;51:1315-24.
43. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 1999;55:190-7.
44. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003;90:367-78.
45. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994;50:337-49.
46. Thall PF, Simon R, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995;14:357-79.
47. Thall PF, Wooten L, Tannir N. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials 2005;2:467-78.
48. Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials 2008;5:93-106.
49. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975;31:103-15.
50. Efron B. International Symposium on Hodgkin's Diseas. Session 6. Survival data and prognosis. Invited discussion: Forcing a sequential experiment to be balanced. Natl Cancer Inst Monogr 1973;36:571-2.
51. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc 1969;64:131-46.
52. Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc 1978;73:840-3.
53. Rosenberger WF, Stallard N, Ivanova A, et al. Optimal adaptive designs for binary response trials. Biometrics 2001;57:909-13.
54. Eisele JR. The doubly adaptive biased coin design for sequential clinical trials. Journal of Statistical Planning and Inference 1994;38:249-61.
55. Hf F, Zhang LX. Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials. Ann Statist 2004;32:268-301.
56. Thall PF, Wathen KJ. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859-66.
57. Lee JJ, Gu XM, Liu SY. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 2010;7:584-96.
58. Yin G, Chen N, Lee JJ. Phase II trial design with Bayesian adaptive randomization and predictive probability. J R Stat Soc Ser C Appl Stat 2012;61.
59. Korn EL, Freidlin B. Outcome--adaptive randomization: is it useful? J Clin Oncol 2011;29:771-6.
60. Lee JJ, Chen N, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res 2012;18:4498-507.
61. Berry DA, Muller P, Grieve AP, et al. Adaptive Bayesian designs for dose-ranging drug trials, In: Gatsonis C, Kass RE, Carlin B, et al. eds. Case Studies in Bayesian Statistics, Volume V. New York: Springer-Verlag, 2001.
62. Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Statistics in Medicine 2014;33:2206-21.
63. Gooley TA, Martin PJ, Fisher LD, et al. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin Trials 1994;15:450-62.
64. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998;54:251-64.
65. O'Quigley J, Hughes MD, Fenton T. Dose-finding designs for HIV studies. Biometrics 2001;57:1018-29.
66. Yin G, Li Y, Ji Y. Bayesian dose-finding in phase I/II trials using toxicity and efficacy odds ratio. Biometrics 2006;62:777-84.
67. Huang X, Biswas S, Oki Y, et al. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007;63:429-36.
68. Yuan Y, Yin G. Bayesian phase I/II drug-combination trial design in oncology. Ann Appl Stat 2011;5:924-42.
69. Hoering A, LeBlanc M, Crowley J. Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents. Clin Cancer Res 2011;17:640-6.
70. Inoue LYT, Thall P, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002;58:823-31.
71. Huang X, Ning J, Li Y, et al. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 2009;28:1680-9.
72. Stallard N. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Stat Med 2010;29:959-71.
73. Kimani PK, Stallard N, Hutton JL. Dose selection in seamless phase II/III clinical trials based on efficacy and safety. Stat Med 2009;28:917-36.
74. Bischoff W, Miller F. A seamless phase II/III design with sample-size reestimation. J Biopharm Stat 2009;19:595-609.
75. Wason J, Magirr D, Law M, et al. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2013. [Epub ahead of print].
76. Sydes MR, Parmar MK, James ND, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009;10:39.
77. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
78. Sledge GW. What is targeted therapy? J Clin Oncol 2005;23:1614-15.
79. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
80. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60.
81. Sargent DJ, Mandrekar SJ. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clin Trials 2013;10:647-52.
82. Mandrekar SJ, Sargent DJ. A review of phase II trial designs for initial marker validation. Contemp Clin Trials 2013;36:597-604.
83. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29:222-30.
84. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-27.
85. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506-12.
86. Simon R, Maitournam A. Perspective evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-63.
87. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39.
88. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 2005;23:5094-98.
89. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93.
90. Willyard C. "Basket studies" will hold intricate data for cancer drug approvals. Nat Med 2013;19:655.
91. Lillie EO, Patay B, Diamant J, et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011;8:161-73.
92. Friends of Cancer Research (2013) Design of a lung cancer master protocol. Available online: http://www.focr.org/events/design-lung-cancer-master-protocol
93. Simon R. Biomarker based clinical trial design. Chin Clin Oncol 2014;3:39.
94. Zhou X, Liu S, Kim ES, et al. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008;5:181-93.
95. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
96. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012;18:638-44.
97. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
98. Carrie P. I-SPY 2 breast cancer clinical trial launches nationwide. Cancer 2010;116:3308.
99. Quantum Leap (2013) I-SPY 2 Trial graduates 2 new drugs. Available online: http://www.quantumleaphealth.org/spy-2-trial-graduates-2-new-drugs-press-release/
100. Lee JJ, Chen N. Software for design of clinical trials. In: Crowley J, Hoering A. eds. Handbook of Statistics in Clinical Oncology, 3rd ed. Boca Raton, FL: Chapman and Hall/CRC Press, 2011.
101. Chow SC, Chang M. Adaptive design methods in clinical trials -- a review. Orphanet J Rare Dis 2008;3:11.
102. Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 2009;43:539-56.